Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition

a technology of thioflavin derivatives and in vivo imaging, which is applied in the direction of drug compositions, organic chemistry, nervous disorders, etc., can solve the problems of delayed assessment of neuritic plaque counts, difficulty, and unknown time of ons

Inactive Publication Date: 2008-06-26
UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION
View PDF11 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0020]It is therefore one embodiment of the present invention to provide compounds which allow for a safe and specific method for diagnosing AD before death by in vivo imaging of amyloid in brain parenchyma.
[0021]It is another embodiment of the present invention to provide an approach for identifying AD amyloid deposits in brain before a patient's death, using a high-affinity probe for amyloid which has low toxicity, can cross the blood-brain barrier, and can distinguish AD brain from normal brain.

Problems solved by technology

AD can strike persons as young as 40-50 years of age, yet, because the presence of the disease is difficult to determine without dangerous brain biopsy, the time of onset is unknown.
Unfortunately, assessment of neuritic plaque counts must be delayed until after death.
Difficulties arise with this technology, however, because the apolipoprotein E4 allele is only a risk factor for AD, not a disease marker.
These methods for diagnosing AD have not been proven to detect AD in all patients, particularly at early stages of the disease and are relatively invasive, requiring a spinal tap.
The major disadvantage of antibody probes is the difficulty in getting these large molecules across the blood-brain barrier.
There is no convincing functional evidence that abnormalities in the blood-brain barrier reliably exist in AD.
However, these peptides share all of the disadvantages of antibodies.
The inability to assess amyloid deposition in AD until after death impedes the study of this devastating illness.
Even though various attempts have been made to diagnose AD in vivo, currently, there are no antemortem probes for brain amyloid.
Thus, no in vivo method for AD diagnosis has been demonstrated to meet these criteria.
Release of a known carcinogen from a therapeutic compound is unacceptable.
A second problem with diazo dye metabolism is that much of the administered drug is metabolized by intestinal bacteria prior to absorption.
This lowered bioavailability remains a disadvantage even if the metabolites released are innocuous.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition
  • Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition
  • Thioflavin derivatives for use in the antemortem diagnosis of alzheimers disease and in vivo imaging and prevention of amyloid deposition

Examples

Experimental program
Comparison scheme
Effect test

examples

[0094]All of the reagents used in the synthesis were purchased from Aldrich Chemical Company and used without further purification. Melting points were determined on MeI-TEMP II and were uncorrected. The 1H NMR spectra of all compounds were measured on Bruker 300 using TMS as internal reference and were in agreement with the assigned structures. The TLC was performed using Silica Gel 60 F254 from EM Sciences and detected under UV lamp. Flash chromatography was performed on silica gel 60 (230-400 mesh. purchased from Mallinckrodt Company. The reverse phase TLC were purchased from Whiteman Company.

synthesis examples

Example 1

Synthesis of Primuline Base Derivatives

[0095]Route 1: Example of the synthesis of Primuline compounds is according to the reaction scheme shown below:

[0096]The primuline derivatives are prepared based on Schubert's method (Schubert, M. Zur Kenntnis der Dehydrothiotoluidin- and Primulin-sulfosäuren, Justus Liebigs Ann. Chem. 558, 10-33, 1947) through condensation of 2-amino-5-methylthiophenol with 2-(p-nitrophenyl)-benzothiazole-6-carboxylic chloride and subsequent reduction of the nitro group with tin chloride in ethanol. Substituted derivatives of primuline base are synthesized with the appropriate substituted p-nitrobenzoylchlorides and R7-R10 substituted 2-aminothiophenol.

[0097]Following the same strategy as above, the other claimed primulin derivatives may be synthesized by substituting the appropriate substituted 3-mercapto-4-aminobenzoic acid derivative (e.g. 2-, 5-, or 6-methyl-3-mercapto-4-aminobenzoic acid), the appropriate 4-nitro-benzoyl chloride derivative (e.g....

example 2

Synthesis of 2-[2-(4′-aminophenyl)-ethylenyl)-benzothiazole derivatives

[0098]Route 3: Example of the synthesis of BTEA-0, 1, 2 and BTAA-0, 1, 2, which are representative of the group of BTEA and BTAA compounds was according to the reaction scheme shown below:

(a) Trans-2-(4-Nitrophenylethenyl)benzothiazole (11)

[0099]trans-4-Nitrocinnamyl chloride 10 (1.77 g, 9.5 mmol, 1.2 eq.) in DMF (20 ml) was added dropwise to a solution of 2-aminothiophenol 9 (1.0 g, 8.0 mmol) in DMF (15 ml) at room temperature. The reaction mixture was stirred at room temperature for overnight. The reaction mixture was poured into a solution of 10% sodium carbonate (100 ml). The participate was collected by filtration under reduced pressure. Recrystallization from methanol gave 1.92 g (85.1%) of the product 11.

(b) 2-(4-Aminophenylethenyl)benzothiazole (12)

[0100]A mixture of 2-(4-nitrophenylethenyl)benthiazole 11 (500 mg, 1.7 mmol) and tin(II) chloride dihydrate (1.18 g, 5.2 mmol) in anhydrous ethanol (20 ml) was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

Description

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS[0001]This application is a Continuation of U.S. Ser. No. 10 / 859,600 filed Jun. 3, 2004 which is a Continuation of Ser. No. 09 / 935,767 filed Aug. 24, 2001 which claims priority from U.S. Provisional Application 60 / 227,601, filed Aug. 24, 2000, incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to the identification of compounds that are suitable for imaging amyloid deposits in living patients. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's Disease. The present invention also relates to therapeutic uses for such compounds.BACKGROUND OF THE INVENTION[0003]Alzheimer's Disease (“AD”) is a neurodegenerative illness characterized by memory loss and other cognitive deficits. McKhann et al., Neurology 34: 939 (1984). It is the most common cause of dementia in the United States. AD can str...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D277/66C07D417/02A61K9/08G01N33/53A61K31/428A61K47/04A61K47/10A61K49/00A61K51/00A61K51/04A61P25/28C07D277/64G01N33/60
CPCA61K31/428A61K51/0497C07D277/66C07D277/64C07B2200/05A61K31/5415A61P25/00A61P25/28
Inventor KLUNK, WILLIAM E.MATHIS, CHESTER A.WANG, YANMING
Owner UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com